Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-cash Items: 2012-2022

  • Ani Pharmaceuticals' Non-cash Items fell 89.89% to $686,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $686,000, marking a year-over-year decrease of 89.89%. This contributed to the annual value of $686,000 for FY2022, which is 11.91% up from last year.
  • As of Q4 2022, Ani Pharmaceuticals' Non-cash Items stood at $686,000, which was down 89.89% from $6.8 million recorded in Q4 2021.
  • Ani Pharmaceuticals' 5-year Non-cash Items high stood at $6.8 million for Q4 2021, and its period low was $372,000 during Q4 2020.
  • Moreover, its 3-year median value for Non-cash Items was $686,000 (2022), whereas its average is $2.6 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 94.50% in 2020, then spiked by 1,724.19% in 2021.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Non-cash Items stood at $2.2 million in 2018, then soared by 204.41% to $6.8 million in 2019, then tumbled by 94.50% to $372,000 in 2020, then surged by 1,724.19% to $6.8 million in 2021, then plummeted by 89.89% to $686,000 in 2022.
  • Its Non-cash Items was $686,000 in Q4 2022, compared to $6.8 million in Q4 2021 and $372,000 in Q4 2020.